Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.75 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166074 | 0.92 | CACNA1B (0.62) | CACNA1BCNR2MEN1RAD52KMT2A | |
| SCHEMBL8151827 | 0.86 | CACNA1B (1.00) | CACNA1BCNR2GNRHRCCNB2CDK1 | |
| SCHEMBL8166118 | 0.86 | CACNA1B (0.87) | CACNA1BCNR2GNRHRNR1H2 | |
| SCHEMBL13401166 | 0.84 | CACNA1B (0.82) | CACNA1BCNR2GNRHR | |
| SCHEMBL13401155 | 0.81 | CACNA1B (0.80) | CACNA1BCNR2GNRHRNR1H2 | |
| SCHEMBL13401168 | 0.81 | CACNA1B (0.78) | CACNA1BCNR2GNRHRMDM2 | |
| SCHEMBL13435729 | 0.81 | CACNA1B (0.74) | CACNA1BCNR2GNRHRNR1H2 | |
| SCHEMBL13401163 | 0.79 | CACNA1B (0.74) | CACNA1BCNR2GNRHR | |
| SCHEMBL13401167 | 0.79 | CACNA1B (0.74) | CACNA1BCNR2GNRHRNR1H2 | |
| SCHEMBL8161881 | 0.78 | CACNA1B (0.70) | CACNA1BCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | CACNA1B 13/4885CNR2 66/4885GNRHR 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.